Medtronic plc (MDT)
Medtronic plc (MDT) is a healthcare company (medical devices) based in Ireland. The share price is $103.23, up 0.34% on the day, which values the company at $132.05B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $103.23+0.34% today
- Market value
- $132.05B
- P/E ratio
- 25.4×last 12 months
- Forward P/E
- 16.1×
- Dividend yield
- 2.77%
- Funk Score
- 54/100
- Against its own history
- About its usual priceusual price $99.57
- 200-week average
- $86.7319% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Medtronic plc in more detail
MDT trades at 25.4× its last twelve months' earnings, 16.1× next year's expected earnings, 3.5× sales. Measured against its own history, the price is 4% above what its usual multiples would imply ($99.57) — about its usual price. It sits 19% above its 200-week average of $86.73.
Over the last five fiscal years Medtronic plc has compounded revenue 3.8% a year, earnings per share 7.0% a year, free cash flow 2.1% a year. Its Funk Score is 54 out of 100 (financial strength 5.6, profitability 6.2, growth 4.1, value 5.7, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Gross margin is shrinking.
10 of the superinvestors tracked here hold MDT, including Matthew McLennan (1.9% of the portfolio), Diamond Hill team (1.4% of the portfolio), Howard Gleicher (1.2% of the portfolio).
Superinvestors holding MDT
10 of the investors tracked here report a position in their latest 13F filing.
- Matthew McLennan First Eagle Investment Management1.89% of portfolio · $1.2B · added · Q3 2026
- Diamond Hill team Diamond Hill Capital Management1.40% of portfolio · $128.2M · trimmed · Q3 2026
- Howard Gleicher Aristotle Capital Management1.15% of portfolio · $506.4M · trimmed · Q3 2026
- Richard Pzena Pzena Investment Management0.78% of portfolio · $265.7M · trimmed · Q3 2026
- Mark Boyar Boyar Asset Management0.40% of portfolio · $643.1K · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox0.32% of portfolio · $595.9M · trimmed · Q3 2026
- Mairs & Power team Mairs & Power0.29% of portfolio · $31.3M · trimmed · Q3 2026
- Ken Griffin Citadel Advisors0.24% of portfolio · $420.4M · added · Q2 2026
- David Shaw (founder) D. E. Shaw & Co.0.21% of portfolio · $344M · added · Q2 2026
- Ray Dalio (founder) Bridgewater Associates0.16% of portfolio · $37.7M · added · Q2 2026
Health Care companies of similar size
- Novo NordiskNVO
- PfizerPFE
- DanaherDHR
- Intuitive SurgicalISRG
- Vertex PharmaceuticalsVRTX
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- CVS HealthCVS
- HCA HealthcareHCA
Side by side:MDT vs BMY (Medtronic plc vs Bristol-Myers Squibb)MDT vs VRTX (Medtronic plc vs Vertex Pharmaceuticals)MDT vs SYK (Medtronic plc vs Stryker)MDT vs MCK (Medtronic plc vs McKesson)MDT vs SNY (Medtronic plc vs Sanofi)
All health care companies by market valueLargest companies in IrelandAll stocks A–Z
Medtronic plc (MDT): questions and answers
What is MDT's P/E ratio?
Medtronic plc trades at 25.4× its last twelve months' earnings and 16.1× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 13.9× to 49.2×, with a median of 28.4×.
What is MDT's PEG ratio?
Medtronic plc's PEG ratio is 1.85 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Medtronic plc's market cap?
Medtronic plc is valued at $132.05B at a share price of $103.23.
Is MDT overvalued or undervalued?
Against its own history, MDT is about its usual price: the price is 4% above the $99.57 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is MDT above its 200-week moving average?
Yes. MDT is 19.0% above its 200-week average of $86.73. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Medtronic plc growing?
Over the last five fiscal years Medtronic plc's revenue grew 3.8% a year and its earnings per share 7.0% a year; over ten years revenue grew 2.3% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Medtronic plc (MDT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MDT
Underlying data: Yahoo Finance; company filings with the SEC.